[HTML][HTML] Outcome measures and biomarkers for clinical trials in hereditary spastic paraplegia: a scoping review
Hereditary spastic paraplegia (HSP) is characterized by progressive lower limb spasticity.
There is no disease-modifying treatment currently available. Therefore, standardized …
There is no disease-modifying treatment currently available. Therefore, standardized …
Outcome Measures and Biomarkers for Clinical Trials in Hereditary Spastic Paraplegia: A Scoping Review
SF Siow, D Yeow, LI Rudaks, F Jia, G Wali, CM Sue… - Genes, 2023 - search.proquest.com
Hereditary spastic paraplegia (HSP) is characterized by progressive lower limb spasticity.
There is no disease-modifying treatment currently available. Therefore, standardized …
There is no disease-modifying treatment currently available. Therefore, standardized …
Outcome Measures and Biomarkers for Clinical Trials in Hereditary Spastic Paraplegia: A Scoping Review.
SF Siow, D Yeow, LI Rudaks, F Jia, G Wali, CM Sue… - …, 2023 - search.ebscohost.com
Hereditary spastic paraplegia (HSP) is characterized by progressive lower limb spasticity.
There is no disease-modifying treatment currently available. Therefore, standardized …
There is no disease-modifying treatment currently available. Therefore, standardized …
[HTML][HTML] Outcome Measures and Biomarkers for Clinical Trials in Hereditary Spastic Paraplegia: A Scoping Review
SF Siow, D Yeow, LI Rudaks, F Jia, G Wali, CM Sue… - Genes, 2023 - ncbi.nlm.nih.gov
Hereditary spastic paraplegia (HSP) is characterized by progressive lower limb spasticity.
There is no disease-modifying treatment currently available. Therefore, standardized …
There is no disease-modifying treatment currently available. Therefore, standardized …
Outcome Measures and Biomarkers for Clinical Trials in Hereditary Spastic Paraplegia: A Scoping Review.
SF Siow, D Yeow, LI Rudaks, F Jia, G Wali, CM Sue… - Genes, 2023 - europepmc.org
Hereditary spastic paraplegia (HSP) is characterized by progressive lower limb spasticity.
There is no disease-modifying treatment currently available. Therefore, standardized …
There is no disease-modifying treatment currently available. Therefore, standardized …
[PDF][PDF] Outcome Measures and Biomarkers for Clinical Trials in Hereditary Spastic Paraplegia: A Scoping Review
SF Siow, D Yeow, LI Rudaks, F Jia, G Wali, CM Sue… - 2023 - researchgate.net
Hereditary spastic paraplegia (HSP) is characterized by progressive lower limb spasticity.
There is no disease-modifying treatment currently available. Therefore, standardized …
There is no disease-modifying treatment currently available. Therefore, standardized …
Outcome Measures and Biomarkers for Clinical Trials in Hereditary Spastic Paraplegia: A Scoping Review
SF Siow, D Yeow, LI Rudaks, F Jia, G Wali… - …, 2023 - pubmed.ncbi.nlm.nih.gov
Hereditary spastic paraplegia (HSP) is characterized by progressive lower limb spasticity.
There is no disease-modifying treatment currently available. Therefore, standardized …
There is no disease-modifying treatment currently available. Therefore, standardized …
Outcome Measures and Biomarkers for Clinical Trials in Hereditary Spastic Paraplegia: A Scoping Review.
SF Siow, D Yeow, LI Rudaks, F Jia, G Wali, CM Sue… - Genes, 2023 - go.gale.com
Hereditary spastic paraplegia (HSP) is characterized by progressive lower limb spasticity.
There is no disease-modifying treatment currently available. Therefore, standardized …
There is no disease-modifying treatment currently available. Therefore, standardized …
Outcome Measures and Biomarkers for Clinical Trials in Hereditary Spastic Paraplegia: A Scoping Review.
SF Siow, D Yeow, LI Rudaks, F Jia, G Wali, CM Sue… - Genes, 2023 - europepmc.org
Hereditary spastic paraplegia (HSP) is characterized by progressive lower limb spasticity.
There is no disease-modifying treatment currently available. Therefore, standardized …
There is no disease-modifying treatment currently available. Therefore, standardized …